A detailed history of Armistice Capital, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Armistice Capital, LLC holds 5,096,000 shares of SUPN stock, worth $181 Million. This represents 2.64% of its overall portfolio holdings.

Number of Shares
5,096,000
Previous 5,272,000 3.34%
Holding current value
$181 Million
Previous $141 Million 12.67%
% of portfolio
2.64%
Previous 1.83%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$25.77 - $35.16 $4.54 Million - $6.19 Million
-176,000 Reduced 3.34%
5,096,000 $159 Million
Q2 2024

Aug 14, 2024

BUY
$25.99 - $33.85 $44.2 Million - $57.5 Million
1,700,000 Added 47.59%
5,272,000 $141 Million
Q1 2024

May 15, 2024

SELL
$27.11 - $35.17 $29.2 Million - $37.9 Million
-1,078,000 Reduced 23.18%
3,572,000 $122 Million
Q4 2023

Feb 13, 2024

SELL
$22.72 - $29.68 $10 Million - $13.1 Million
-442,000 Reduced 8.68%
4,650,000 $135 Million
Q3 2023

Nov 14, 2023

BUY
$27.57 - $32.91 $1.54 Million - $1.84 Million
56,000 Added 1.11%
5,092,000 $140 Million
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $20.5 Million - $26.6 Million
686,000 Added 15.77%
5,036,000 $151 Million
Q1 2023

May 15, 2023

SELL
$34.93 - $42.03 $209,580 - $252,180
-6,000 Reduced 0.14%
4,350,000 $158 Million
Q4 2022

Feb 14, 2023

SELL
$31.09 - $37.88 $7.37 Million - $8.98 Million
-237,004 Reduced 5.16%
4,356,000 $155 Million
Q3 2022

Nov 14, 2022

SELL
$28.79 - $35.41 $3.43 Million - $4.21 Million
-118,996 Reduced 2.53%
4,593,004 $155 Million
Q2 2022

Aug 15, 2022

BUY
$25.33 - $34.25 $40.8 Million - $55.2 Million
1,612,000 Added 52.0%
4,712,000 $136 Million
Q1 2022

May 16, 2022

SELL
$28.51 - $32.9 $29.5 Million - $34.1 Million
-1,036,000 Reduced 25.05%
3,100,000 $100 Million
Q4 2021

Feb 14, 2022

BUY
$26.37 - $34.22 $6.22 Million - $8.08 Million
236,000 Added 6.05%
4,136,000 $121 Million
Q3 2021

Nov 15, 2021

BUY
$23.54 - $31.39 $13.6 Million - $18.1 Million
576,000 Added 17.33%
3,900,000 $104 Million
Q2 2021

Aug 16, 2021

SELL
$26.72 - $33.19 $2.35 Million - $2.92 Million
-88,000 Reduced 2.58%
3,324,000 $102 Million
Q1 2021

May 17, 2021

BUY
$24.15 - $31.45 $7.05 Million - $9.18 Million
292,000 Added 9.36%
3,412,000 $89.3 Million
Q4 2020

Feb 16, 2021

SELL
$17.7 - $25.81 $1.42 Million - $2.06 Million
-80,000 Reduced 2.5%
3,120,000 $78.5 Million
Q3 2020

Nov 16, 2020

BUY
$20.2 - $25.05 $20 Million - $24.8 Million
992,000 Added 44.93%
3,200,000 $66.7 Million
Q2 2020

Aug 14, 2020

SELL
$17.09 - $24.89 $13.5 Million - $19.7 Million
-792,000 Reduced 26.4%
2,208,000 $52.4 Million
Q1 2020

May 15, 2020

BUY
$14.45 - $24.69 $18.6 Million - $31.8 Million
1,288,000 Added 75.23%
3,000,000 $54 Million
Q4 2019

Feb 14, 2020

BUY
$19.93 - $29.13 $34.1 Million - $49.9 Million
1,712,000 New
1,712,000 $40.6 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.9B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Armistice Capital, LLC Portfolio

Follow Armistice Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Armistice Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Armistice Capital, LLC with notifications on news.